Molecular cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervical intraepithelial neoplasia and cervical carcinomas

被引:16
作者
Kuglik, P. [1 ,3 ]
Kasikova, K. [1 ,3 ]
Smetana, J. [1 ,3 ]
Vallova, V. [1 ,3 ]
Lastuvkova, A. [1 ]
Moukova, L. [2 ]
Cvanova, M. [4 ,5 ]
Brozova, L. [4 ,5 ]
机构
[1] Masaryk Univ, Inst Expt Biol, Lab Mol Cytogenet, Brno, Czech Republic
[2] Masaryk Mem Canc Inst, Dept Gynecol Oncol, Brno, Czech Republic
[3] Univ Hosp, Dept Med Genet, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic
[5] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic
关键词
cervical cancer; cervical dysplasia; HPV infection; hTERC amplification; MYC amplification; FISH; array-CGH; TELOMERASE RNA GENE; COMPARATIVE GENOMIC HYBRIDIZATION; VASCULAR SPACE INVOLVEMENT; C-MYC; EPITHELIAL-CELLS; IN-SITU; CLINICAL-SIGNIFICANCE; TERC; HPV; SPECIMENS;
D O I
10.4149/neo_2015_017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is known that cervical cancer develop from precancerous intraepithelial neoplasia (CIN) which is characterized by series of genetic abnormalities. The progression of CIN to cervical carcinoma has been associated especially with the genomic integration of oncogenic human papilloma virus (HPV) and gain of the human telomerase RNA gene hTERC (3q26) and MYC (8q24). In this study, cytology specimens of cervical intraepithelial neoplasia and cervical carcinoma from 74 Czech women were analyzed using the triple-color Cervical FISH Probe Kit designed for identification of HPV infected cells and copy number aberration of the hTERC and MYC genes. HPV-positivity exhibited 70% of patients with premalignant lesions (CIN I - CIN III, carcinoma in situ), chromosomal changes were found in 53.3% of cases - MYC amplification had 33.3% of women with CIN I - CIN III and 50% with carcinoma in situ. Amplification of hTERC was detected in 16.7% of patient with CIN I, in 50% with CIN II, in 58.3% with CIN III and in 66.7% with carcinoma in situ. Based on HPV-positivity and the occurrence of chromosomal aberrations, patients were divided into high-, intermediate- and low-risk group. Among women with cervical carcinomas, HPV infection was detected in 90.1% of specimens and chromosomal aberrations were found in 87.5% of samples. Amplification of MYC gene was detected in 25% and hTERC gene in 62.5% of patients. According to the histopathological grade of tumors, MYC gene amplification occurred more frequently in specimens of spinocellular carcinoma than adenocarcinoma (p=0.029). We found no association between the frequency of cytogenetic lesions and the incidence of lymphangiogenesis or lymph node metastases in cervical carcinoma patients. Simultaneous hTERC and MYC genes amplification was significantly more frequent in samples of cervical carcinomas than in premalignant lesions (p=0.008). In a cohort of 26 patients with cervical carcinoma we used oligo-based GGH+SNP microarray technique for the high resolution mapping of copy number changes of hTERC and MYC genes. We found that recurrent gain of genetic material in chromosome 3q26 area carrying hTERC gene of size 43.6 Mb between 3q25.1-3qter and duplication of 3q were the most common genomic identifications of amplified gene. In MYC locus array-CGH profiling identified duplication of 8q and trisomy 8 as frequent genomic changes. Our work confirmed that in cervical carcinoma gains of hTERC and MYC genes are specific genomic changes associated with developing of malignant phenotype. We also showed that in premalignant stages HPV-FISH assay can be used as an effective diagnostic procedure to identify patients carrying highly risking HPV infection and chromosomal aberrations associated with this malignancy.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 35 条
[1]   The c-myc activation in cervical carcinomas and HPV 16 infections [J].
Abba, MC ;
Laguens, RM ;
Dulout, FN ;
Golijow, CD .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2004, 557 (02) :151-158
[2]   3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases [J].
Alameda, Francesc ;
Espinet, Blanca ;
Corzo, Cristina ;
Munoz, Raquel ;
Bellosillo, Beatriz ;
Lloveras, Belen ;
Pijuan, Lara ;
Gimeno, Javier ;
Salido, Marta ;
Sole, Francesc ;
Carreras, Ramon ;
Serrano, Sergi .
HUMAN PATHOLOGY, 2009, 40 (10) :1474-1478
[3]   Evaluation of quantity and staining pattern of human papillomavirus (HPV)-infected epithelial cells in thin-layer cervical specimens using optimized HPV-CARD assay [J].
Algeciras-Schimnich, Alicia ;
Policht, Frank ;
Sitailo, Svetlana ;
Song, Minghao ;
Morrison, Larry ;
Sokolova, Irina .
CANCER CYTOPATHOLOGY, 2007, 111 (05) :330-338
[4]   Progressive genetic aberrations detected by comparative genomic hybridisation in squamous cell cervical cancer [J].
Allen, DG ;
White, DJ ;
Hutchins, AM ;
Scurry, JP ;
Tabrizi, SN ;
Garland, SM ;
Armes, JE .
BRITISH JOURNAL OF CANCER, 2000, 83 (12) :1659-1663
[5]  
Busmanis I., 1998, Annals Academy of Medicine Singapore, V27, P671
[6]   Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma [J].
Caraway, Nancy P. ;
Khanna, Abha ;
Dawlett, Marilyn ;
Guo, Ming ;
Guo, Nina ;
Lin, E. ;
Katz, Ruth L. .
GYNECOLOGIC ONCOLOGY, 2008, 110 (01) :37-42
[7]   Significance of Human Telomerase RNA Gene Amplification Detection for Cervical Cancer Screening [J].
Chen, Shao-Min ;
Lin, Wei ;
Liu, Xin ;
Zhang, You-Zhong .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (05) :2063-2068
[8]   Genomic amplification patterns of human telomerase RNA gene and C-MYC in liquid-based cytological specimens used for the detection of high-grade cervical intraepithelial neoplasia [J].
Chen, Shaomin ;
Yang, Ziyan ;
Zhang, Yun ;
Qiao, Yunbo ;
Cui, Baoxia ;
Zhang, Youzhong ;
Kong, Beihua .
DIAGNOSTIC PATHOLOGY, 2012, 7 :40
[9]   Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? [J].
Creasman, WT ;
Kohler, MF .
GYNECOLOGIC ONCOLOGY, 2004, 92 (02) :525-529
[10]  
Eid M M, 2011, Gulf J Oncolog, P18